An interventional study of TL01 light treatment in Psoriasis, sponsored by University of Aberdeen. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-03-25.
Sponsored by University of Aberdeen · Not applicable, Interventional, and Diagnostic
This is a pilot study to investigate the effect of TL01 narrow band UVB therapy on the resident dermal dendritic cells characterized by expression of CD1c and CD141. These cells were reported to have a role in induction of tolerogenic regulatory T cells and production of IL-10. The investigators proposed to investigate the effect of NB-UVB on these subsets of cells after two weeks of treatment to provide better understanding of the mechanism of action of light treatment.
Six patients with plaque psoriasis were recruited from the phototherapy unit. These patients were referred by their dermatologist to receive narrow-band UVB (TL01) light treatment. Two 6 mm lesional skin punch biopsies were taken at baseline and 2 weeks after commencing the light treatment to study the effect of light on innate immune cells involved in psoriasis pathogenesis.
1,928 studies on the registry are indexed under Psoriasis; 234 are open to participants now.
This study's enrollment of 6 is below the median of 70 across 1,472 interventional studies indexed under Psoriasis.
Browse Psoriasis studies →University of Aberdeen is the lead sponsor of 175 studies on the registry; 23 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
patients currently on antipsoriatic treatment.
routine treatment with a CE marked device that has been used for this disease for many years
Device: TL01 light treatment
Patients received treatment in TL01 cabinet three sessions weekly according to a standard escalating protocol based on minimal erythema dose. Standard dose ranges between 0.55 and 3.13J/cm2.
Also known as: Waldmnn Gmbh cabinet
determination of the effect of TL01 NB-UVB on numbers of CD1c and CD141 cells
no adverse events recorded after two weeks of TL01 treatment
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.